Diagnostics in a Post PAMA Marketplace
Biotechnology Industry Organization
1201 Maryland Avenue Southwest
Washington, DC 20024
On April 1, the Protecting Access to Medicare Act of 2014 (PAMA) was enacted into law. Section 216, entitled Improving Medicare Policies for Clinical Diagnostic Laboratory Tests, modernizes the Medicare payment system for clinical laboratory tests with the establishment of a market-based payment system. This is the most significant modernization of the Clinical Laboratory Fee Schedule (CLFS) since the introduction of the CLFS in 1984.
Please click here for a summary of the CLFS Reform Provisions.
A Panel Discussion With
Dan Todd, Health Policy Advisor, Senate Finance Committee - PAMA Overview / CLFS Reform to Market Based Pricing
Elaine Jeter, M.D., Medical Director, Palmetto GBA - What to Expect from Private Payers and the Role of MolDx
Louis Jacques, M.D., ADVI (former Director, Coverage & Analysis Group, CMS) - The role of CMS and FDA in Clinical Utility
Brian Carey, Foley Hoag, LLP - Issues to Watch for Implementation
Marc Samuels, ADVI
Bruce Quinn, M.D., Ph.D., Foley Hoag LLP